Lucid Diagnostics Inc. filed its Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, disclosing a net loss of $6.7 million for the third quarter and $32.3 million for the nine months ended September 30, 2026.

Key Highlights

  • Third-quarter revenue: $1,203 thousand for the three months ended September 30, 2026, compared with $1,211 thousand in the same period of 2025, according to the filing.
  • Nine-month revenue: $3,932 thousand for the nine months ended September 30, 2026, up from $3,202 thousand in the comparable 2025 period, as reported.
  • Net loss: $6,677 thousand for Q3 2026 and $32,273 thousand for the nine months ended September 30, 2026, attributable to Lucid Diagnostics Inc. common stockholders.
  • Cash position: $17,993 thousand as of September 30, 2026, down from $34,705 thousand at December 31, 2025, per the balance sheet.
  • Senior Secured Convertible Notes fair value: $17,300 thousand as of September 30, 2026, compared with $24,000 thousand at December 31, 2025.
  • Shares outstanding: 203,243,970 shares as of September 30, 2026, and 206,977,800 shares as of November 10, 2026, according to the filing.
  • Accumulated deficit: $319,355 thousand as of September 30, 2026, increased from $274,335 thousand at December 31, 2025.

Lucid Diagnostics Q3 2026 Financial Results: Revenue, Losses, and Balance Sheet

According to the filing, Lucid Diagnostics Inc. (NASDAQ:LUCD) reported revenue of $1,203 thousand for the three months ended September 30, 2026, a slight decrease from $1,211 thousand in the prior-year quarter. For the nine months ended September 30, 2026, revenue totaled $3,932 thousand, compared with $3,202 thousand in the nine months ended September 30, 2025. Total operating expenses for the nine-month period were $41,122 thousand, up from $38,831 thousand in the same period of 2025, driven in part by sales and marketing expenses of $16,029 thousand and general and administrative expenses of $16,723 thousand.

The company disclosed an operating loss of $12,276 thousand for Q3 2026 and $37,190 thousand for the nine-month period. Other income for the nine months included a change in fair value of the Senior Secured Convertible Note of $4,722 thousand, compared with a loss of $5,297 thousand in the same period of 2025. After accounting for other income and expense items, the net loss attributable to Lucid Diagnostics Inc. was $6,677 thousand for Q3 2026 and $32,273 thousand for the nine-month period. Net loss per share attributable to common stockholders was $0.03 (basic and diluted) for the quarter and $0.26 for the nine months ended September 30, 2026.

On the balance sheet, total assets were $27,857 thousand as of September 30, 2026, down from $40,445 thousand at December 31, 2025. The company's total stockholders' equity stood at $5,932 thousand as of September 30, 2026, compared with $10,936 thousand at year-end 2025. The Series B and Series B-1 Convertible Preferred Stock, which carried a balance of $54,274 thousand at December 31, 2025, showed 0 shares issued and outstanding as of September 30, 2026, per the filing. Common shares authorized were increased to 400,000,000 as of September 30, 2026, from 300,000,000 at December 31, 2025.

What Was Disclosed

Lucid Diagnostics filed its Q3 2026 Form 10-Q reporting quarterly revenue of $1,203 thousand, a net loss of $6,677 thousand, cash of $17,993 thousand, and an accumulated deficit of $319,355 thousand as of September 30, 2026.